Literature DB >> 3689979

Effects of anti-estrogens on bone in castrated and intact female rats.

V C Jordan1, E Phelps, J U Lindgren.   

Abstract

The effects of the antiestrogens tamoxifen and keoxifene on the bone density of intact and ovariectomized female rats were determined after 4 months of therapy. The antiestrogens did not cause a decrease in bone density in intact animals, although uterine wet weight did decrease. Ovariectomy caused an increase in body weight (25%) and a significant decrease in femur density (P less than 0.01). Antiestrogens did not further decrease the bone density of ovariectomized rats but rather helped to maintain bone density. Antiestrogens as well as estrogen (oral estradiol benzoate 25 micrograms daily) helped to maintain bone density in the range observed for the intact rats, but inhibited estrogen stimulation of uterine weight. These contrasting pharmacological actions of antiestrogens suggest that patients receiving long-term adjuvant tamoxifen therapy for breast cancer should be evaluated to determine whether tamoxifen can retard the development of osteoporosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3689979     DOI: 10.1007/bf01806132

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  20 in total

1.  Antiestrogens in the treatment of breast cancer.

Authors:  S S Legha; S K Carter
Journal:  Cancer Treat Rev       Date:  1976-12       Impact factor: 12.111

2.  Long-term adjuvant tamoxifen study: clinical update.

Authors:  D C Tormey; P Rasmussen; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

3.  Biological activity of 25-hydroxyergocalciferol in rats.

Authors:  T Suda; H F DeLuca; Y Tanaka
Journal:  J Nutr       Date:  1970-09       Impact factor: 4.798

4.  Osteoporosis after oophorectomy in the mature female rat and the effect of oestrogen and-or progestogen replacement therapy in its prevention.

Authors:  J M Aitken; E Armstrong; J B Anderson
Journal:  J Endocrinol       Date:  1972-10       Impact factor: 4.286

5.  Changes in skeletal mass and fragility with castration in the rat; a model of osteoporosis.

Authors:  P D Saville
Journal:  J Am Geriatr Soc       Date:  1969-02       Impact factor: 5.562

Review 6.  The pharmacology and clinical uses of tamoxifen.

Authors:  B J Furr; V C Jordan
Journal:  Pharmacol Ther       Date:  1984       Impact factor: 12.310

7.  Effect of 1-alpha-hydroxyvitamin D3 on osteoporosis in rats induced by oophorectomy.

Authors:  J U Lindgren; T S Lindholm
Journal:  Calcif Tissue Int       Date:  1979-04-17       Impact factor: 4.333

8.  Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo.

Authors:  F J Cummings; R Gray; T E Davis; D C Tormey; J E Harris; G Falkson; J Arseneau
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

9.  Clomiphene protects against osteoporosis in the mature ovariectomized rat.

Authors:  P T Beall; L K Misra; R L Young; H J Spjut; H J Evans; A LeBlanc
Journal:  Calcif Tissue Int       Date:  1984-01       Impact factor: 4.333

10.  Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.

Authors:  M M Gottardis; V C Jordan
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

View more
  70 in total

Review 1.  The selective oestrogen receptor modulation: evolution and clinical applications.

Authors:  D W Purdie; S A Beardsworth
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

2.  Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer.

Authors:  V C Jordan; M Morrow
Journal:  BMJ       Date:  1999-08-07

3.  Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer.

Authors:  Jamal Zidan; Zohar Keidar; Walid Basher; Ora Israel
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

4.  Profile of V. Craig Jordan.

Authors:  Sujata Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-16       Impact factor: 11.205

5.  Beyond raloxifene for the prevention of osteoporosis and breast cancer.

Authors:  V C Jordan
Journal:  Br J Pharmacol       Date:  2006-11-20       Impact factor: 8.739

6.  Ovarian status influences the skeletal effects of tamoxifen in adult rats.

Authors:  J D Sibonga; G L Evans; E R Hauck; N H Bell; R T Turner
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 7.  The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens.

Authors:  D A Tonetti; V C Jordan
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

Review 8.  Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.

Authors:  V Craig Jordan; Joan Lewis-Wambi; Helen Kim; Heather Cunliffe; Eric Ariazi; Catherine G N Sharma; Heather A Shupp; Ramona Swaby
Journal:  Breast       Date:  2007-08-24       Impact factor: 4.380

9.  Long-range transcriptional control of progesterone receptor gene expression.

Authors:  Jamie Bonéy-Montoya; Yvonne S Ziegler; Carol D Curtis; Jonathan A Montoya; Ann M Nardulli
Journal:  Mol Endocrinol       Date:  2009-12-01

Review 10.  Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.

Authors:  Jing Peng; Surojeet Sengupta; V Craig Jordan
Journal:  Anticancer Agents Med Chem       Date:  2009-06       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.